ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1874

Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests

Louise Parker1, Kevin Howell2, Voon H. Ong3 and Christopher P.Denton4, 1Centre for Rheumatology and Connective Diseases, UCL Medical School and Royal Free Hosp, London, United Kingdom, 2Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, 3Rheumatology, UCL Division of Medicine, London, United Kingdom, 4Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ANA, Capillaroscopy, capillary microscopy and connective tissue diseases, Raynaud's phenomenon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Raynaud’s phenomenon is common but can progress to definite connective tissue disease. We have observed long term follow up of an unselected consecutive cohort of isolated RP to define frequency of progression and negative predictive value of nailfold capillaroscopy (NC) and ANA testing. Cases attending a dedicated Raynaud’s clinic were stratified according to baseline assessment and observed serially. Frequency of SSc or connective tissue diagnosis at presentation and progression of nailfold capillary abnormality or development of positive ANA was determined during routine follow up.

Methods: Cases of suspected RP were referred from primary care to a dedicated Raynaud’s clinic. In addition to clinical management of Raynaud’s symptoms all cases had baseline ANA testing and nailfold capillaroscopy (NC) for stratification and diagnosis. There were also clinically evaluated for presence of connective tissue disease (CTD). Those with a SSc specific ANA were referred for evaluation comprehensive assessment in a specialized CTD clinic. In cases of isolated RP without evidence of CTD but considered at risk of progression annual review was performed. The number of cases with significant evolution was determined.

Results: Patients with definite symptoms of RP were assessed by clinical examination, autoantibody testing and capillaroscopy (n=457). Of these, 119 cases were assessed as potential secondary RP and were reviewed at least once. Mean (SD) follow up of RP cases was 2.0 (1.8) years with a range of 1 to 12 years. A total of 350/457 (76.7%) had negative ANA, an additional 3/119 (2.5%) became ANA positive during follow-up. NC confirmed 335/457 (73.3%) had normal capillaries and 7/119 (5.9%) developed abnormal NVC during follow up, none with ANA evolution. At first assessment 23/457 (5%) had SSc specific ANA positivity (centromere, Scl-70, RNApol3, U3-RNP reactivity) and these were referred to the CTD clinic for evaluation and review. Of these, 12/23 (52.2%) had abnormal NVC and 8/23 (34.8%) had clinical evidence of connective tissue disease. 4 fulfilled classification criteria for SSc (2 limited and 2 diffuse SSc). No SSc pattern ANA was observed in other patients during follow up. No cases developed defined CTD within the follow up period (ANA+/NC+). 28 ANA positive cases were reviewed and none developed NC progression to abnormal. Thus, overall the rate of significant change in these tests was low and no patients with negative ANA and normal NC progressed.

Conclusion: Feasibility and utility of systematic baseline assessment of cases presenting with isolated RP is confirmed. Routine assessment of ANA and NC is known to be useful in identifying cases of RP with SSc specific ANA, including new SSc diagnosis, and those at risk of long term progression. However, these tests are often normal and then the rate of progression is very low. In this cohort cases with negative tests did not show any clinical progression confirming that these tests have a robust negative predictive value.


Disclosure: L. Parker, None; K. Howell, None; V. H. Ong, None; C. P.Denton, GSK, Celgene, Actelion, Bayer, Sanofi, Roche, Inventiva, 5,GSK, Actelion, Roche, Inventiva, 2.

To cite this abstract in AMA style:

Parker L, Howell K, Ong VH, P.Denton C. Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/low-rate-of-progression-in-cases-of-isolated-raynauds-phenomenon-screened-by-nailfold-videocapillaroscopy-and-antinuclear-antibody-status-supports-negative-predictive-value-of-these-tests/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-rate-of-progression-in-cases-of-isolated-raynauds-phenomenon-screened-by-nailfold-videocapillaroscopy-and-antinuclear-antibody-status-supports-negative-predictive-value-of-these-tests/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology